• Research Frontiers Reports Third Quarter 2022 Financial Results and Will Host a Conference Call at 4:30p.m. Today

    来源: Nasdaq GlobeNewswire / 03 11月 2022 16:01:02   America/New_York

    WOODBURY, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its September 30, 2022 third quarter. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments.

     Who: Joseph M. Harary, President & CEO
     Date/Time: November 3, 2022, 4:30 PM ET
     Dial-in Information:1-888-334-5785
     Replay: Available on Friday, November 4, 2022 for 90 days at https://smartglass-ir.com/

    Key Comments:

    1.After adjusting for one-time events relating to the timing of payments and new and amended license agreements entered into in 2021, fee income was higher in the third quarter of 2022 as compared to the third quarter of 2021, primarily as a result of higher fee income from the automotive and aircraft segments. Fee income was also higher in the third quarter of 2022 as compared to the second quarter of 2022, primarily as a result of higher fee income from the automotive and aircraft segments.
      
    2.This year Cadillac had multiple high-profile public exhibitions of its Cadillac Celestiq which enters series production next year and will be produced at the General Motors Tech Center in Warren Michigan. The Celestiq is Cadillac’s all-electric luxury flagship, and features a four-quadrant SPD-SmartGlass roof using Research Frontiers variable tint technology. An additional car was introduced by another European automobile manufacturer in the third quarter of 2022 using Research Frontiers SPD-SmartGlass technology in its panoramic glass roof.
      
    3.The Company expects revenue in all market segments to increase as new car models, aircraft, trains and other products using the Company’s SPD-SmartGlass technology are introduced into the market.
      
    4.Operating expenses decreased by $83,548, and research and development expenses increased by $13,941 in the third quarter of 2022 as compared to the same period in 2021.
      
    5.The Company’s net loss was $483,729 ($0.02 per common share) for the three months ended September 30, 2022 as compared to net income of $21,614 ($0.00 per common share) for the three months ended September 30, 2021. The Company’s net loss was $258,109 lower in the third quarter of 2022 compared to the previous quarter.
      
    6.As of September 30, 2022, the Company had cash and cash equivalents of approximately $4.8 million and working capital of approximately $5.2 million. The Company has no debt and expects to have sufficient working capital for at least the next five years of operations.

    For more details, please see the Company’s Quarterly Report on Form 10-Q which was filed today with the SEC, the contents of which are incorporated by reference herein.

    About Research Frontiers

    Research Frontiers (Nasdaq: REFR) is a publicly traded technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to over 40 companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, please visit our website at www.SmartGlass.com, and on Facebook, Twitter, LinkedIn and YouTube.

    Note: From time to time Research Frontiers may issue forward-looking statements which involve risks and uncertainties. This press release contains forward-looking statements. Actual results, especially those reliant on activities by third parties, could differ and are not guaranteed. Any forward-looking statements should be considered accordingly. “SPD-Smart” and “SPD-SmartGlass” are trademarks of Research Frontiers Inc. Celestiq is a trademark of General Motors.

    CONTACT:
    Joseph M. Harary
    President and CEO
    Research Frontiers Inc.
    +1-516-364-1902
    Info@SmartGlass.com

    RESEARCH FRONTIERS INCORPORATED
    Condensed Consolidated Balance Sheets

      September 30, 2022  December 31, 2021 
      (Unaudited)    
           
    Assets        
    Current assets:        
    Cash and cash equivalents $4,798,150  $269,964 
    Marketable securities  -   2,755,111 
    Royalty receivables, net of reserves of $1,168,450 in 2022 and $1,016,678 in 2021  534,529   831,636 
    Prepaid expenses and other current assets  166,571   92,931 
    Total current assets  5,499,250   3,949,642 
             
    Fixed assets, net  72,556   92,954 
    Operating lease ROU assets  360,164   469,824 
    Deposits and other assets  33,567   33,567 
    Total assets $5,965,537  $4,545,987 
             
    Liabilities and Shareholders’ Equity        
             
    Current liabilities:        
    Current portion of operating lease liability $193,182  $182,091 
    Accounts payable  38,010   66,460 
    Accrued expenses and other  32,946   49,385 
    Deferred revenue  3,586   - 
    Total current liabilities  267,724   297,936 
             
    Operating lease liability, net of current portion  317,805   464,128 
    Total liabilities  585,529   762,064 
             
    Shareholders’ equity:        
    Common stock, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 33,150,396 in 2022 and 31,650,396 in 2021  3,315   3,165 
    Additional paid-in capital  126,917,736   123,467,886 
    Accumulated deficit  (121,541,043)  (119,687,128)
    Total shareholders’ equity  5,380,008   3,783,923 
             
    Total liabilities and shareholders’ equity $5,965,537  $4,545,987 


    See accompanying notes to condensed consolidated financial statements.

    RESEARCH FRONTIERS INCORPORATED
    Condensed Consolidated Statements of Operations
    (Unaudited)

      Nine months ended September 30,  Three months ended September 30, 
      2022  2021  2022  2021 
                 
    Fee income $409,783  $1,050,526  $150,443  $723,465 
                     
    Operating expenses  1,770,414   1,699,698   487,476   571,024 
    Research and development  444,413   420,203   149,156   135,215 
    Total expenses  2,214,827   2,119,901   636,632   706,239 
                     
    Operating income (loss)  (1,805,044)  (1,069,375)  (486,189)  17,226 
                     
    Net investment (loss) income  (48,871)  5,747   2,460   4,388 
                     
    Net income (loss) $(1,853,915) $(1,063,628) $(483,729) $21,614 
                     
    Basic and diluted net income (loss) per common share $(0.06) $(0.03) $(0.02) $0.00 
                     
    Weighted average number of common shares outstanding  31,710,179   31,645,227   31,829,744   31,650,396 


    See accompanying notes to condensed consolidated financial statements.

    RESEARCH FRONTIERS INCORPORATED
    Condensed Consolidated Statements of Shareholders’ Equity
    (Unaudited)

    For the nine months ended September 30, 2021 and 2022

      Common Stock  Additional
    Paid-in
      Accumulated    
      Shares  Amount  Capital  Deficit  Total 
    Balance, January 1, 2021  31,575,786  $3,158  $123,164,623  $(117,840,776) $5,327,005 
                         
    Exercise of options  74,610   7   86,255   -   86,262 
    Net loss  -   -   -   (1,063,628)  (1,063,628)
    Balance, September 30, 2021  31,650,396  $3,165  $123,250,878  $(118,904,404) $4,349,639 
                         
    Balance, January 1, 2022  31,650,396  $3,165  $123,467,886  $(119,687,128) $3,783,923 
                         
    Issuance of common stock and warrants  1,500,000   150   3,449,850   -   3,450,000 
    Net loss  -   -   -   (1,853,915)  (1,853,915)
    Balance, September 30, 2022  33,150,396  $3,315  $126,917,736  $(121,541,043) $5,380,008 


    For the three months ended September 30, 2021 and 2022

      Common Stock  Additional Paid-in  Accumulated    
      Shares  Amount  Capital  Deficit  Total 
    Balance, July 1, 2021  31,650,396  $3,165  $123,250,878  $(118,926,018) $4,328,025 
                         
    Net income  -   -   -   21,614   21,614 
    Balance, September 30, 2021  31,650,396  $3,165  $123,250,878  $(118,904,404) $4,349,639 
                         
    Balance, July 1, 2022  31,650,396  $3,165  $123,467,886  $(121,057,314) $2,413,737 
                         
    Issuance of common stock and warrants  1,500,000   150   3,449,850   -   3,450,000 
    Net loss  -   -   -   (483,729)  (483,729)
    Balance, September 30, 2022  33,150,396  $3,315  $126,917,736  $(121,541,043) $5,380,008 


    See accompanying notes to condensed consolidated financial statements.

    RESEARCH FRONTIERS INCORPORATED
    Condensed Consolidated Statements of Cash Flows
    (Unaudited)

      For the nine months ended September 30, 
      2022  2021 
    Cash flows from operating activities:        
    Net loss $(1,853,915) $(1,063,628)
    Adjustments to reconcile net loss to net cash used in operating activities:        
    Depreciation and amortization  21,614   22,414 
    Realized loss on marketable securities  60,143   - 
    Unrealized loss on marketable securities  -   5,545 
    Bad debts  151,772   - 
    ROU asset amortization  109,660   109,963 
    Change in assets and liabilities:        
    Royalty receivables  145,335   (754,679)
    Prepaid expenses and other current assets  (73,640)  (102,183)
    Accounts payable and accrued expenses  (44,889)  24,959 
    Deferred revenue  3,586   13,304 
    Operating lease liability  (135,232)  (123,539)
    Net cash used in operating activities  (1,615,566)  (1,867,844)
             
    Cash flows from investing activities:        
    Purchases of fixed assets  (1,216)  (966)
    Purchases of marketable securities  -   (3,433,633)
    Proceeds from sales of marketable securities  2,694,968   650,000 
    Net cash provided by (used in) investing activities  2,693,752   (2,784,599)
             
    Cash flows from financing activities:        
    Proceeds from sale of common stock and warrants  3,450,000   - 
    Proceeds from exercise of options  -   86,262 
    Net cash provided by financing activities  3,450,000   86,262 
             
    Net increase (decrease) in cash and cash equivalents  4,528,186   (4,566,181)
             
    Cash and cash equivalents at beginning of period  269,964   4,772,705 
    Cash and cash equivalents at end of period $4,798,150  $206,524 

    See accompanying notes to condensed consolidated financial statements.


    Primary Logo

分享